WHO ICTRP trial
Mechanism of action of the quadratus lumborum block
EUCTR2017-004221-32-BE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2017-004221-32-BE |
|---|---|
| Public title | Mechanism of action of the quadratus lumborum block |
| Scientific title | Mechanism of action of the quadratus lumborum block |
| Primary sponsor | Department of Anesthesia Reanimation of University of Liege |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Belgium |
| Conditions | Patients undergoing abdominal laparoscopy or laparotomy;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
| Interventions | Trade Name: Naropin 0,75% (R): Ropivacaine 0,75%: (Astra-Zeneca) Iomeron 300: 61,24% w/v of iomeprol equivalent to 30% iodine or 300mg iodine/ml (Bracco UK Limited) Pharmaceutical Form: |
| Registration date | Jun 21, 2018 |
| Target size | 60 |
| Secondary IDs | 2017PG2 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: